Seres Therapeutics Inc (MCRB) Unusual Options Activity Today

Checking MCRB unusual options activity helps you spot when traders are making outsized bets on Seres Therapeutics Inc before the broader market catches on. Seres Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor MCRB unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching MCRB unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking MCRB unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and MCRB unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants.

In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Catalysts rarely arrive without a footprint, and MCRB unusual options activity is often where that footprint shows up first. Our scanner tracks Seres Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at MCRB unusual options volume on the call side or chasing put sweeps, Seres Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.